The purpose of this study is to evaluate the relative bioavailability for the new iberdomide powder for reconstitution formulation relative to the reference capsule formulation and to assess the effect of food on the pharmacokinetics of powder for reconstitution formulation in healthy adult participants.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
32
Specified dose on specified days
Local Institution - 0001
Daytona Beach, Florida, United States
Maximum Observed Plasma Concentration (Cmax)
Time frame: Up to 72 hours post-dose for Period 1 and Period 2 (each period is 4 days, with a 5-9 day washout between each dose)
Area Under the Plasma Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUC(0-T))
Time frame: Up to 72 hours post-dose for Period 1 and Period 2 (each period is 4 days, with a 5-9 day washout between each dose)
Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF))
Time frame: Up to 72 hours post-dose for Period 1 and Period 2 (each period is 4 days, with a 5-9 day washout between each dose)
Number of Participants with Adverse Events
Time frame: Up to 28 days
Number of Participants with Vital Sign Abnormalities
Time frame: Up to 20 days
Number of Participants with Clinical Laboratory Abnormalities
Time frame: Up to 20 days
Number of Participants with Electrocardiogram Abnormalities
Time frame: Up to 20 days
Number of Participants with Physical Examination Abnormalities
Time frame: Up to 20 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.